trial · primary record
Tocilizumab
Metastatic Non-Small Cell Lung Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 43 |
| Primary completion | 2029-10-31 |
| Primary endpoint | Safety of adding Tocilizumab to Standard of Care Immunotherapy |
| Registry ID | NCT07889232 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:37.682Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07889232
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Tocilizumab · approval
- Tocilizumab · compound